Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 9/20 | 0.61 |
| ▸ | CASP5 | P51878 | 9/20 | 0.61 |
| ▸ | CASP4 | P49662 | 7/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | GBA1 | P04062 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2771547 | 0.98 | CASP1 (0.59) | CASP1CASP5CASP4HRH4GBA1 | |
| SCHEMBL2773410 | 0.96 | CASP1 (0.56) | CASP1CASP5CASP4HRH4GBA1 | |
| Aethimidinum SCHEMBL29352989 | 0.92 | CASP1 (0.50) | CASP1CASP5CASP4HRH4GBA1 | |
| SCHEMBL9159902 | 0.90 | CASP1 (0.81) | CASP1CASP5CASP4HRH4CYP1A2 | |
| SCHEMBL9545737 | 0.90 | CASP1 (0.81) | CASP1CASP5CASP4HRH4CYP1A2 | |
| SCHEMBL1697668 | 0.87 | CASP1 (0.48) | CASP1CASP5CASP4HRH4CYP1A2 | |
| SCHEMBL24851307 | 0.87 | CASP1 (0.49) | CASP1CASP5CASP4HRH4GBA1 | |
| SCHEMBL19479135 | 0.86 | CYP1A2 (0.62) | CASP1CASP5CASP4HRH4CYP1A2 | |
| SCHEMBL15334687 | 0.85 | SMN1; SMN2 (0.48) | CASP1CASP5CASP4CYP1A2KMT2A | |
| SCHEMBL29754406 | 0.85 | CASP1 (0.80) | CASP1CASP5CASP4HRH4GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5225555-A | Processes for purification of 2,4-di(1-pyrrolidinyl)-6-chloropyrimidine | THE UPJOHN COMPANY (US) | 1993-07-06 | — | — | US | claimed |
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | disclosed |
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2178848-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2010-04-28 | — | — | EP | disclosed |
| EP-2152675-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | IPSEN PHARMA S.A.S. (FR) | 2010-02-17 | — | — | EP | disclosed |
| US-7576241-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2009-08-18 | — | — | US | disclosed |
| US-7576241-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2009-08-18 | — | — | US | disclosed |
| US-7576241-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2009-08-18 | — | — | US | disclosed |
| WO-2009034258-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2009-03-19 | — | — | WO | disclosed |
| US-7473779-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-01-06 | — | — | US | disclosed |
| US-4996318-A | Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke | THE UPJOHN COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0358676-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0354920-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1990-02-21 | — | — | EP | disclosed |
| EP-0293078-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1988-11-30 | — | — | EP | disclosed |
| WO-1988008424-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1988-11-03 | — | — | WO | disclosed |
| WO-1988007527-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1988-10-06 | — | — | WO | disclosed |
| EP-0263213-A1 | C20 Through C26 amino steroids | THE UPJOHN COMPANY (US) | 1988-04-13 | — | — | EP | disclosed |
| WO-1987007895-A1 | ANDROSTANE-TYPE AND CORTICAL AMINOESTERS | THE UPJOHN COMPANY (US) | 1987-12-30 | — | — | WO | disclosed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | disclosed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137275-A1 | TRIAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF CDC25 PHOSPHATASE | CDC25A, CDC25B, CDC25C | CASP1 3771/4885CASP5 1933/4885CASP4 3033/4885 |
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | CDC25B, CDC25A, CDC25C | CASP1 4179/4885CASP5 2010/4885CASP4 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.